Editas Medicine (EDIT) Proxy filing summary

Executive summary

• The annual meeting will be held virtually on June 17, 2026, with voting available online, by phone, mail, or during the meeting.

• Key business highlights include a strategic shift to in vivo gene editing, nomination of EDIT-401 as a lead candidate, and extension of the cash runway into Q3 2027.

• The company emphasizes strong corporate governance, regular stockholder engagement, and a commitment to diversity, inclusion, and sustainability.

Voting matters and shareholder proposals

• Stockholders will vote on: (1) election of two Class I directors for three-year terms, (2) advisory approval of executive compensation, and (3) ratification of PricewaterhouseCoopers LLP as independent auditor for 2026.

• The board recommends voting FOR all proposals.

• No other business is anticipated at the meeting.

Board of directors and corporate governance

• The board consists of six members, with a majority being independent and all committees fully independent.

• Board refreshment is ongoing, with recent additions and a mandatory retirement age of 75.

• The board is divided into three classes with staggered three-year terms.

• Committees include Audit, Compensation, and Nominating and Corporate Governance, each with defined charters and responsibilities.

• Annual board and committee self-evaluations and director commitment policies are in place.